PubRank

C K Osborne

Author PubWeight™ 192.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999 11.18
2 Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993 4.45
3 Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994 4.28
4 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992 3.63
5 Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995 3.61
6 The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980 3.34
7 Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 1999 2.58
8 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998 2.55
9 Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999 2.32
10 Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985 2.13
11 Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987 2.12
12 Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 2001 2.07
13 Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998 2.06
14 ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000 2.05
15 Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992 2.05
16 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999 2.00
17 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000 1.98
18 Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999 1.89
19 The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 1994 1.87
20 Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998 1.85
21 Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984 1.84
22 Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995 1.81
23 Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst 1999 1.75
24 Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 1989 1.70
25 Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994 1.67
26 Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005 1.63
27 Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996 1.58
28 Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 1988 1.57
29 Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 1999 1.57
30 Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989 1.56
31 Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999 1.55
32 HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992 1.55
33 Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 1987 1.54
34 The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993 1.54
35 Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science 1983 1.52
36 Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983 1.52
37 Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000 1.50
38 A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol 2011 1.45
39 Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol 1996 1.43
40 Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998 1.42
41 Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983 1.37
42 Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993 1.36
43 Oestrogen receptors and breast cancer. BMJ 1997 1.35
44 Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001 1.34
45 Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976 1.32
46 Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res 1980 1.29
47 Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996 1.26
48 Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994 1.24
49 bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997 1.23
50 Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989 1.22
51 Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol 1998 1.21
52 bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998 1.21
53 HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998 1.20
54 Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985 1.19
55 Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 1980 1.19
56 Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997 1.17
57 Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 1984 1.16
58 Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 2000 1.16
59 Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000 1.16
60 Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 1994 1.11
61 Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997 1.10
62 Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res 1978 1.09
63 Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995 1.08
64 Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994 1.07
65 Histologic progression in non-Hodgkin's lymphoma. Blood 1982 1.06
66 Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997 1.06
67 Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res 1998 1.05
68 An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer 1983 1.05
69 Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat 1981 1.03
70 Systemic mirnas as potential biomarkers for malignancy. Int J Cancer 2012 1.02
71 Prognostic factors in breast cancer. Semin Oncol 1992 1.02
72 DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010 1.02
73 Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998 1.01
74 Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995 1.01
75 Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res 1984 0.98
76 Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer 2005 0.97
77 Heat shock proteins and drug resistance. Breast Cancer Res Treat 1994 0.96
78 High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer 2001 0.96
79 In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med 1977 0.96
80 Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003 0.95
81 Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 1998 0.95
82 Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003 0.94
83 The use of steroïd hormone receptors in the treatment of human breast cancer: a review. Bull Cancer 1979 0.94
84 Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol 1998 0.94
85 Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 1997 0.94
86 HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res 2000 0.94
87 Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 2012 0.94
88 Steroid hormone receptors in the management of human breast cancer. Ann Clin Res 1980 0.94
89 Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat 1994 0.93
90 Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest 1981 0.93
91 Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 1990 0.93
92 Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 1988 0.93
93 Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992 0.92
94 Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol 1982 0.91
95 Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001 0.91
96 Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother Pharmacol 1989 0.91
97 Modern approaches to the treatment of breast cancer. Blood 1980 0.90
98 Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells. Science 1996 0.90
99 Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ 1994 0.90
100 Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res 1988 0.90
101 Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997 0.89
102 Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene 1989 0.88
103 Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 1997 0.88
104 Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 1992 0.87
105 Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol 1997 0.87
106 Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 1992 0.87
107 Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976 0.87
108 Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 1992 0.87
109 Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 1997 0.86
110 The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 1996 0.86
111 A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 1991 0.85
112 Steroid hormone receptors and carcinoma of the breast. Am J Physiol 1982 0.85
113 Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994 0.85
114 Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991 0.84
115 The use of restriction fragment polymorphisms to identify the cell line MCF-7. Breast Cancer Res Treat 1986 0.84
116 Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am 1978 0.83
117 Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol 1987 0.82
118 Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat 1981 0.82
119 Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993 0.81
120 Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res 1991 0.81
121 Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat 1989 0.81
122 Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1981 0.81
123 DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst 1989 0.81
124 Prognostic factors in breast cancer. Hematol Oncol Clin North Am 1989 0.80
125 Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood 1980 0.80
126 Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res 1995 0.80
127 Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 1993 0.80
128 Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. Breast Cancer Res Treat 1998 0.80
129 Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res 2001 0.80
130 Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1996 0.80
131 Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res Treat 1985 0.79
132 Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res 1994 0.79
133 Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer. Cancer Treat Res 1988 0.79
134 Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res 1979 0.78
135 Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. J Clin Oncol 1989 0.78
136 Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol 1981 0.78
137 Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs 1991 0.77
138 Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res Treat 1987 0.77
139 Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 1983 0.77
140 Antitumor activity and murine pharmacokinetics of parenteral acronycine. Cancer Res 1989 0.77
141 Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells 1982 0.77
142 Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat 1992 0.77
143 Breast cancer mortality and diet in the United States. Cancer Res 1979 0.77
144 Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 1996 0.76
145 Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 1991 0.76
146 Insulin stimulation of fatty acid synthesis in human breast cancer cells. J Natl Cancer Inst 1977 0.76
147 A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs 1985 0.75
148 Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med 1979 0.75
149 One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol 1993 0.75
150 Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs 1983 0.75
151 Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1983 0.75
152 Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr 1986 0.75
153 Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res 2001 0.75
154 Effect of methemoglobin on in vivo RBC lipid peroxidation. Aerosp Med 1973 0.75
155 Adjuvant treatment of node-negative breast cancer. Tex Med 1989 0.75
156 Hormone receptors in the management of breast cancer. Tex Med 1984 0.75
157 Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep 1984 0.75
158 Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr 1992 0.75
159 Pain control in breast cancer. A panel discussion. Breast Cancer Res Treat 1989 0.75
160 Rapid identification of transfected plasmid expression vectors in cells by PCR. Biotechniques 1991 0.75
161 Polypeptide growth factors: their potential value in the management of breast cancer patients. Cancer Treat Res 1992 0.75
162 The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat 1988 0.75
163 Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs 1994 0.75
164 Bisantrene, biological and clinical effects. Cancer Treat Rev 1984 0.75
165 Breast cancer. Breast Oncology Workgroup, Legislative Task Force on Cancer in Texas. Tex Med 1987 0.75
166 Resistance to endocrine therapy. A panel discussion. Breast Cancer Res Treat 1987 0.75
167 Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat 1981 0.75
168 Effects of hyperoxia on white blood cells. I. In vivo changes in the total white blood cell counts of normal rats. Aerosp Med 1970 0.75
169 Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg 1985 0.75
170 Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM. World J Surg 1985 0.75
171 Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr 1992 0.75
172 Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res 1989 0.75
173 Adjuvant chemotherapy. CA Cancer J Clin 1986 0.75
174 Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem 1985 0.75
175 Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 1987 0.75
176 Megestrol acetate in breast cancer--a panel discussion. Breast Cancer Res Treat 1989 0.75